RE:RE:Jazz Pharmaceutical BUYOUT.It's quite possible medipharm is not on the radar of JAZZ because they are one of many participating the the CBD REC market...a market JAZZ doesn't care to be involved in....I don't think JAZZ monitors all REC CBD companies...this Wednesday they will be startled to learn a small Canadian REC participant is actually a fully FDA globally certified cannabinoid pharmaceutical Corp...however they may of caught on to this once the DMF was initiated...they could be watching ready to pounce as we speak..it the patent challenge is successful they would be stupid not to act.